Clinical trialsCompany release
Adagene doses first patient in Phase 1 trial of double-masked HER2×CD3 engager ADG138
Adagene Inc. (ADAG) · Thu 19 Nov 2026
The first-in-human study of ADG138, a SAFEbody-masked bispecific T-cell engager, enrols heavily pretreated patients with HER2-positive advanced solid tumours, including some who progressed after HER2-directed antibody-drug conjugates.
Adagene Inc. announced on 19 November 2026 that the first patient has been dosed in a Phase 1 trial of ADG138, its HER2×CD3 bispecific T-cell engager that uses the company's SAFEbody double-masking technology.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Adagene Inc. ↗
Article written by VigiEye from the official source (Adagene Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
PMV Pharma reports 48% response rate for rezatapopt in platinum-resistant ovarian cancer
🇺🇸 PMV Pharmaceuticals, Inc. (PMVP) · Fri 20 Nov 2026
J&J's Tremfya beats placebo in Phase 4 STAR axial psoriatic arthritis study at Week 24
Johnson & Johnson EMEA · Fri 20 Nov 2026
Immutep reports 81% 12-month disease-free survival in neoadjuvant soft tissue sarcoma trial
IMMUTEP Ltd (IMMP) · Fri 20 Nov 2026
BfArM lists ArcRoyal field safety notice for procedure trays containing BD Connecta Stopcock
🇩🇪 BfArM field safety notices · Thu 19 Nov 2026
FDA allows Alpha Tau to double REGAIN glioblastoma trial to 20 patients
Alpha Tau Medical Ltd. (DRTS) · Thu 19 Nov 2026
Health Canada posts Type II recall of Philips Bridge Prep Kit over guidewire resistance
🇨🇦 Health Canada · Thu 19 Nov 2026